Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at ...

Q3 2025 Management View Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to ...

Get Q3 2025 earnings insights on DiaMedica Therapeutics (DMAC): clinical progress, DM199 trial updates, financials, and strategic outlook.

Amid a burgeoning artificial intelligence (AI) landscape, giving investors an overabundance of stocks trying to capitalize on ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

Discover the word Alabamians most struggle to pronounce in 2025 and join millions of Americans searching for the right way to ...

The government shutdown has ended, but Senate Democrats didn’t get a key provision they were fighting for: extending the ...

Strategic process -- Formal engagement with Evercore concluded; current focus is on Phase III clinical execution, with ...

Good day, ladies and gentlemen, and welcome to your Capstone Green Energy Earnings Conference Call and Webcast for the financial results for the second quarter fiscal year 2026 ended on September 30, ...

At CEATEC 2025, NEC unveiled an excellent example of how generative AI can improve real-world safety. Its AI Driving Diagnosis system, ...

SOMERSET, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a U.S.-based ...

Oakford Valtrion is a platform built to guide novice traders in starting their journey and to help seasoned traders discover ...